



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider transcatheter aortic valve replacement (TAVR), performed via the transfemoral or transapical approach, for patients with aortic stenosis to be **eligible for coverage**.

Patient Selection Criteria

Coverage eligibility will be met for transcatheter aortic valve replacement (TAVR), performed via the transfemoral or transapical approach, for patients with aortic stenosis when all of the following conditions are present:

- Severe aortic stenosis (see *Note*¹) with a calcified aortic annulus;
- New York Heart Association (NYHA) heart failure Class II, III or IV symptoms;
- Left ventricular ejection fraction greater than 20%; AND
- Patient is not an operable candidate for open surgery, as judged by at least two cardiovascular specialists (cardiologist and/or cardiac surgeon); or patient is an operable candidate but is at high risk for open surgery (see *Note*²).

*Note*¹:

Severe aortic stenosis is defined by one or more of the following criteria:

- An aortic valve area of less than 0.8 cm²
- A mean aortic valve gradient greater than 40 mmHg
- A jet velocity greater than 4.0 m/s

*Note*²:

U.S. Food and Drug Administration (FDA) definition of high risk for open surgery:

- Society of Thoracic Surgeons predicted operative risk score of 8% or higher; or
- Judged by a heart team, which includes an experienced cardiac surgeon and a cardiologist, to have an expected mortality risk of 15% or higher for open surgery.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers transcatheter aortic valve replacement (TAVR) is considered to be **investigational*** for all other indications, including but not limited to:

- Patients with a degenerated bio-prosthetic valve (“Valve-in-Valve” implantation);
- Procedures performed via the transaxillary, transiliac, transaortic, or other approaches.

The use of transcatheter aortic valve replacement (TAVR), performed via the transfemoral or transapical approach, for patients with aortic stenosis when patient selection criteria are not met is considered to be **investigational.***

Background/Overview

Transcatheter aortic valve implantation (TAVI; also known as transcatheter aortic valve replacement or TAVR) is a potential alternative treatment for patients with severe aortic stenosis. Many patients with aortic stenosis are very elderly and/or have multiple medical comorbidities, thus indicating a high, often prohibitive, risk for surgery. This procedure is being evaluated as an alternative to open surgery for high-risk patients with aortic stenosis and as an alternative to nonsurgical therapy for patients with a prohibitive risk for surgery.

Aortic Stenosis

Aortic stenosis is defined as narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Progressive calcification of the aortic valve is the most common etiology in North America and Europe, while rheumatic fever is the most common etiology in developing countries. Congenital abnormalities of the aortic valve, most commonly a bicuspid valve, increase the risk for aortic stenosis, but aortic stenosis can also occur in a normal aortic valve. Risk factors for calcification of a congenitally normal valve mirror those for atherosclerotic vascular disease, including advanced age, male gender, smoking, hypertension, and hyperlipidemia. Thus, the pathogenesis of calcific aortic stenosis is thought to be similar to that of atherosclerosis, ie, deposition of atherogenic lipids and infiltration of inflammatory cells, followed by progressive calcification.

The natural history of aortic stenosis involves a long asymptomatic period, with slowly progressive narrowing of the valve until the stenosis reaches the severe stage. At this time, symptoms of dyspnea, chest pain, and/or dizziness/syncope often occur and the disorder progresses rapidly. Treatment of aortic stenosis is primarily surgical, involving replacement of the diseased valve with a bioprosthetic or mechanical valve by open heart surgery.

Burden of Illness

Aortic stenosis is a relatively common disorder of elderly patients and is the most common acquired valve disorder in the U.S. Approximately 2% to 4% of individuals older than 65 years of age have evidence of significant aortic stenosis, increasing up to 8% of individuals by age 85 years. In the Helsinki Aging Study, a population-based study of 501 patients aged 75 to 86 years, the prevalence of severe aortic stenosis by



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

echocardiography was estimated to be 2.9%. In the U.S., more than 50,000 aortic valve replacements (AVRs) are performed annually due to severe aortic stenosis.

Aortic stenosis does not cause substantial morbidity or mortality when the disease is mild or moderate in severity. By the time it reaches the severe stage, there is an untreated mortality rate of approximately 50% within 2 years. Open surgical repair is an effective treatment for reversing aortic stenosis, and artificial valves have demonstrated good durability for periods of up to 20 years. However, these benefits are accompanied by a perioperative mortality of approximately 3% to 4% and substantial morbidity, both of which increase with advancing age.

Unmet Needs

Many patients with severe, symptomatic aortic stenosis are poor operative candidates. Approximately 30% of patients presenting with severe aortic stenosis do not undergo open surgery due to factors such as advanced age, advanced left ventricular dysfunction, or multiple medical comorbidities. For patients who are not surgical candidates, medical therapy can partially alleviate the symptoms of aortic stenosis but does not affect the underlying disease progression. Percutaneous balloon valvuloplasty can be performed, but this procedure has less than optimal outcomes. Balloon valvuloplasty can improve symptoms and increase flow across the stenotic valve but is associated with high rates of complications such as stroke, myocardial infarction (MI), and aortic regurgitation. In addition, restenosis can occur rapidly, and there is no improvement in mortality. As a result, there is a large unmet need for less invasive treatments for aortic stenosis in patients who are at increased risk for open surgery.

Transcatheter Aortic Valve Implantation

Transcatheter aortic valve implantation has been developed in response to this unmet need and is intended as an alternative treatment for patients in whom surgery is not an option due to prohibitive surgical risk or for patients who are at high risk for open surgery. The procedure is performed percutaneously, most often through the transfemoral artery approach. It can also be done through the subclavian artery approach and transapically using mediastinoscopy. Balloon valvuloplasty is first performed in order to open up the stenotic area. This is followed by passage of a bioprosthetic artificial valve across the native aortic valve. The valve is initially compressed to allow passage across the native valve and is then expanded and secured to the underlying aortic-valve annulus. The procedure is performed on the beating heart without the need for cardiopulmonary bypass.

There are at least two transcatheter aortic valve devices being used. The Edwards SAPIEN transcatheter heart-valve system^{TM†} (Edwards Lifesciences, Irvine, CA) is a tri-leaflet bioprosthetic porcine valve that is contained within a stainless steel frame. This device first received FDA approval in 2011, with expanded indications for approval granted in 2012 and 2013.

The Medtronic CoreValve ReValving System^{TM†} is a second transcatheter valve system under testing. This device is a porcine bioprosthetic valve that is sewn within a self-expanding nitinol frame. It is inserted via the transfemoral artery approach and has also been inserted via the subclavian artery approach. This device has also been approved for use in Europe since 2007 but has not yet received FDA approval in the U.S.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration

The Sapien Transcatheter Heart Valve System (Edwards LifeSciences, Irvine, CA) received original FDA approval in November 2011 for patients with severe aortic stenosis who are not eligible for open-heart procedures and have a calcified aortic annulus. In 2012, an additional FDA premarket approval (PMA) was granted for the Edwards SAPIEN transcatheter heart valve Model 9000TFX (Edwards LifeSciences, Irvine, CA) with expanded indications for use. Approval was granted for both the transfemoral and transapical approach. For the transfemoral approach, patient indications were broadened to include patients who are at high risk for open surgery. For the transapical approach, approval was granted for patients who are at high risk for open surgery. In September 2013, the FDA expanded the indications for the transapical approach to include both inoperable patients and patients who are at high risk for open surgery. As a result, as of September 2013, the Sapien Transcatheter Heart Valve System is approved for both high risk and inoperable patients when used by either the transapical or transfemoral approach.

Centers for Medicare and Medicaid Services (CMS)

The CMS published a decision memo on the use of transcatheter aortic valve replacement in May 2012. This memo indicated that CMS covers TAVI when used according to FDA indications when the following conditions are met:

- Device has FDA approval
- Two cardiac surgeons agree with indications for the procedure
- The patient is under the care of a heart team, and the hospital meets qualifications for performing TAVI.

The memo also stated that TAVR could be covered for non FDA-approved indications under the Coverage with Evidence Development (CED) program. The following is a summary of the main conditions required for CED:

- Transcatheter aortic valve implantation is performed within a clinical study that has the following characteristics:
 - o The clinical study must adhere to the standards of scientific integrity and relevance to the Medicare population
 - o The study must address quality of life (QOL) and adverse events at follow-up periods of 1 year or longer.

Rationale/Source

The evidence on TAVI consists of many uncontrolled case series and one pivotal randomized controlled trial (RCT)—the PARTNER trial. These studies report on two potential populations for TAVI: (1) patients who are not surgical candidates, and (2) patients who are high risk for surgery but still considered to be surgical candidates. The evidence on these two groups of patients will be discussed separately.

Does TAVI improve outcomes for patients with aortic stenosis who are not suitable candidates for open surgery?

Systematic Reviews

Systematic reviews on this question consist of studies that evaluate results from case series. An Agency for Healthcare Research and Quality (AHRQ)–sponsored systematic review in 2010 reviewed 84 publications

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406
Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014

enrolling 2375 patients. Implantation was successful in 94% of patients overall, with higher success rates reported in more recent publications. The aggregate 30-day survival was 89% across all studies. Adverse event rates were reported in the larger case series, with an estimated 30-day rate of major cardiovascular adverse events and stroke of 8%.

A second systematic review was published in 2011 by Figulla et al. This review included studies that enrolled symptomatic patients with severe aortic stenosis, had a mean age of 75 years or older, reported on 10 or more patients, and had a follow-up duration of 12 months or more. A total of 12 studies met these criteria and were compared to a group of 11 studies that treated severe aortic stenosis with nonsurgical therapy. The procedural success in these studies ranged from 86% to 100%, and the 30-day mortality ranged from 5.3 to 23%. The combined mean survival rate at 1 year was 75.9% (confidence interval [CI], 73.3 to 78.4). This 1-year survival rate compared favorably to medical therapy, which was estimated to be 62.4% (95% CI, 59.3 to 65.5).

Randomized Controlled Trials

The PARTNER trial was a pivotal multicenter RCT of TAVI performed in the U.S., Canada, and Germany, using the SAPIEN heart-valve system. Leon et al reported results of patients from the PARTNER trial with severe aortic stenosis who were not candidates for open surgery. In order to be classified as unsuitable for open surgery, patients had to have a predicted probability of 50% or higher for death or a serious irreversible condition at 30 days post-surgery. This probability was determined by two surgeon investigators using clinical judgment and the Society of Thoracic Surgery (STS) risk score. The executive committee of the PARTNER trial reviewed all patient selection decisions and approved the classification of patients as unsuitable for surgery. A total of 3105 patients were screened for aortic-valve surgery, and 12% of these were eventually included in the cohort of patients deemed unsuitable for surgery.

A total of 358 patients were randomized to TAVI or usual care. Transcatheter aortic valve implantation was performed by the transfemoral approach under general anesthesia. Standard therapy was determined by the treating clinicians. In most cases (83.8%), standard treatment included balloon valvuloplasty of the aortic valve. A small number of patients (6.7%) underwent open surgical valve replacement, despite the high risk, and another 2.2% of patients underwent TAVI at a center outside the U.S. that was not participating in the trial. The primary outcome was death from any cause over the course of the trial (median follow-up, 1.6 years). A “coprimary” end point was the composite of time to death from any cause or time to repeat hospitalization related to aortic stenosis or TAVI. Secondary end points were cardiovascular mortality, NYHA functional class, the rate of hospitalizations due to aortic stenosis or TAVI, the 6-minute walk test, valve performance as measured by echocardiography, and procedural complications (MI, stroke, acute kidney injury [AKI], vascular complications, and bleeding).

The mean age of enrolled patients was 83.2 years. There were some baseline imbalances in the patient population indicating that the standard therapy group may have had a higher severity of illness. Standardized scores of surgical risk were higher in the standard therapy group. The Logistic EuroSCORE was significantly higher in the standard therapy group compared to the TAVI group (30.4±19.1 vs 26.4±17.2, $p = 0.04$) and the STS score was numerically higher but did not reach statistical significance (12.1±6.1 vs 11.2±5.8, $p = 0.14$). Significantly more patients in the standard therapy group had chronic



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406
Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014

obstructive pulmonary disease (52.5% vs 41.3, $p = 0.04$) and atrial fibrillation (48.8% vs 32.9%, $p = 0.04$), and there was a nonsignificant trend for more patients in the standard therapy group having a lower ejection fraction (51.1 vs 53.9%) and frailty, as determined by prespecified criteria (28.0 vs 18.1%).

Death from any cause at 1 year following enrollment was lower for the TAVI group (30.7% vs 49.7%, $p < 0.001$). This represents a 19% absolute risk reduction, a 38.2% relative risk reduction, and a number needed to treat of 5.3 to prevent one death over a 1-year follow-up. Most secondary outcomes also favored the TAVI group. Cardiovascular death was lower in the TAVI group (19.6% vs 44.1%, $p < 0.001$). The composite of all-cause mortality and repeat hospitalizations was reached by 42.5% of the patients in the TAVI group compared with 70.4% in the standard therapy group. Symptoms and functional status were also superior in the TAVI group. The percent of patients in NYHA Class I or II at 1 year was higher for the TAVI group (74.8% vs 42.0%, $p < 0.001$), and there was a significant improvement in the 6-minute walk test for the TAVI group but not for the standard therapy group (between group comparisons not reported). Subgroup analysis did not report any significant differences in outcomes according to clinical and demographic factors.

Complication rates were higher for the TAVI group. Stroke or transient ischemic attack (TIA) at 1 year was more than twice as frequent for the TAVI group (10.6% vs 4.5%, $p = 0.04$). Major bleeding and vascular complications occurred in a substantial percent of patients undergoing TAVI and were significantly higher than in the standard therapy group (22.3% vs 11.2%, $p = 0.007$; and 32.4% vs. 7.3%, $p < 0.001$, respectively).

Quality of life outcomes from this trial were reported by Reynolds et al in 2012. QOL outcomes were evaluated using the Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score, the Medical Outcomes Study 12-Item Short-Form (SF-12), and the EuroQol (EQ-5D). The number of participants who completed the QOL measures was not clearly reported; estimates from graphical representation show that between 149 and 170 patients in the TAVI group and 138 and 157 patients in the medical therapy group completed baseline QOL measures. At the follow-up time points of 30 days, 6 months, and 12 months, the change in the QOL scores was greater for the TAVI group. At 30 days, the mean difference in the KCCQ was 13.3 points (95% CI, 7.6 to 19.0; $p < 0.001$). This mean difference increased at later time points to 20.8 points (95% CI, 14.7 to 27.0; $p < 0.001$) at 6 months and 26.0 points (95% CI, 18.7 to 33.3; $p < 0.001$) at 12 months. Changes in the SF-12 and EQ-5D measures showed similar patterns.

Two-year outcomes were reported from the PARTNER trial in 2012. Mortality at 2 years was 43.3% in the TAVI group compared to 68.0% in the medical therapy group (hazard ratio [HR], 0.58; 95% CI, 0.36 to 0.92; $p = 0.02$). Cardiovascular mortality was also lower in the TAVI group compared to medical therapy (31.0% vs 62.4%, $p < 0.001$). The rate of hospitalization over the 2-year period was lower in the TAVI group compared to medical therapy (35.0% vs 72.5%, $p < 0.001$).

Case Series

Many case series of TAVI have been published in the last 10 years, the majority of which have included patients who are not candidates for open surgery. However, the selection process for TAVI has largely been subjective, with the expert opinion of the surgeons and/or cardiologists as the main factor determining



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406
Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014

suitability for open surgery. As a result, there may be some overlap in these series with patients who are surgical candidates, but the distinction cannot be easily made from the reported studies. Some of the larger case series are discussed below.

The 2 largest series included in the AHRQ review reported on 646 patients treated with the Medtronic CoreValve and 339 patients treated with the Edwards SAPIEN valve. The CoreValve study by Piazza et al was notable in that it used more objective patient selection criteria than is common in this literature. Their criteria for eligibility included the following: (1) Logistic EuroSCORE of 15% or higher, (2) age of 75 or older, or (3) age of 65 or older with liver cirrhosis, pulmonary insufficiency, pulmonary hypertension, previous cardiac surgery, porcelain aorta, recurrent pulmonary emboli, right ventricular insufficiency, previous chest burns or radiation precluding open surgery, or body mass index (BMI) of 18 kg/m² or less. Procedural success was 97% and 30-day survival was 92%. The 30-day combined rate of death, MI, or stroke was 9.3%. The study by Rodes-Cabou et al was performed in Canada and used Edwards SAPIEN valve. This study had subjective inclusion criteria, relying on the judgment of the participating surgeons to determine eligibility for TAVI. The procedural success rate was 93.3%, and the 30-day mortality was 10.4%. The authors also reported a mortality rate of 22.1% at a median follow-up of 8 months.

Another larger case series was from Germany and reported on 697 patients treated with the CoreValve system. Procedural success was 98.4%, and 30-day mortality was 12.4%. Another large case series from Italy included 663 patients treated with the CoreValve device. Procedural success was 98% and mortality at 1 year was 15%. A notable study was published by Gurvitch et al in 2011 that reported on durability and longer clinical outcomes up to 3 years. Seventy patients who underwent TAVI and survived for greater than 30 days were included. Survival at 1, 2, and 3 years was 81%, 74%, and 61%, respectively. One patient (1.5%) required reoperation during this time period. The valve area decreased from 1.7 (0.4) cm² following the procedure to 1.4 (0.3) cm² at 3 years. Aortic incompetence was trivial or mild in 84% of patients and did not worsen over time.

Section Summary

Numerous case series have demonstrated feasibility and short-term efficacy for TAVI in patients who are not surgical candidates. In the PARTNER B trial, there was a large decrease in all-cause mortality and cardiovascular mortality at 1 year for TAVI compared to standard therapy. Subsequent publications from this same trial reported that the mortality benefit was maintained at 2 years and that QOL was improved for the TAVI group. Baseline group differences were present, indicating that the TAVI group may have been healthier. While these differences are unlikely to account for the degree of mortality benefit reported, they may have resulted in an overestimation of the mortality benefit.

The benefit in mortality was accompanied by an increased stroke risk, as well as substantial increases in vascular complications and major bleeding. There is also uncertainty concerning the generalizability of these results, since patient selection was primarily determined by the judgment of the cardiovascular surgeons and/or cardiologists. It is not known whether this type of decision making by surgeons and cardiologists is reliable across the range of practicing clinicians.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

Does TAVI improve outcomes for high-risk patients with aortic stenosis as an alternative to open surgery?

Systematic Reviews

Several systematic reviews have been published on this question. The evidence in these studies is derived largely from nonrandomized comparative studies, as only 1 RCT has been published (the PARTNER trial). Panchal et al reported results from a meta-analysis of 17 studies that included 4659 patients, 2267 treated with TAVI, and 2392 treated with open surgery. Patients in the TAVI group were more severely ill, as evidenced by a EuroSCORE for predicted 30-day mortality that was higher by a mean of 3.7 points compared to patients undergoing open surgery. On combined analysis, there were no differences between groups on 30-day mortality, mortality at longest follow-up, cardiovascular mortality, MI, stroke, or TIA. Patients in the open surgery group had a higher incidence of major bleeding complications (relative risk, 1.42; 95% CI, 1.20 to 1.67; $p < 0.001$). In a similar meta-analysis that included 17 studies reporting on 4873 patients, there were no differences between TAVI and open surgery in early mortality (odds ratio [OR], 0.92; 95% CI, 0.70 to 1.2) or mid-term mortality, defined as between 3 months and 3 years (HR = 0.99; 95% CI, 0.83 to 1.2).

Randomized Controlled Trials

Results from the cohort of patients in the PARTNER trial who were high risk for open surgery, but still suitable candidates, were published in June 2011. The inclusion and exclusion criteria were generally the same as for the prior cohort, except that these patients were classified as high risk for surgery rather than unsuitable for surgery. For high risk, patients had to have a predicted perioperative mortality of 15% or higher, as determined by a cardiac surgeon and cardiologist using clinical judgment. An STS score of 10 or higher was included as a guide for high risk, but an STS score threshold was not a required criterion for enrollment. The executive committee of the PARTNER trial reviewed all patient selection decisions and approved the classification of patients as high risk for surgery. A total of 3105 patients were screened for aortic valve surgery, and 22.5% of these were eventually included in the cohort of patients deemed high risk for surgery.

A total of 699 patients were randomized to TAVI or usual care. The primary hypothesis was that TAVI was noninferior to open AVR, using a 1-sided noninferiority boundary of 7.5% absolute difference in mortality at 1 year. Transcatheter aortic valve implantation was performed under general anesthesia using the transfemoral approach when possible ($n = 492$). If the transfemoral approach was not possible, transapical approach was used ($n = 207$). The comparison group underwent open AVR. Details of the open procedure were not provided in presentation slides.

The primary outcome was death from any cause at 1-year follow-up. A second powered end point was noninferiority at 1 year for the patients undergoing TAVI by the transfemoral approach. Secondary end points were cardiovascular mortality, NYHA functional class, rehospitalizations, the 6-minute walk test, valve performance as measured by echocardiography, and procedural complications (MI, stroke, AKI, vascular complications, and bleeding). The mean age of enrolled patients was 83.6 years in the TAVI group and 84.5 years in the open AVR group. Other baseline demographics and clinical characteristics were generally well-balanced, except for a trend toward an increased percent of patients in the TAVI group with a creatinine level greater than 2.0 (11.1% vs 7.0%, $p = 0.06$).

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

Death from any cause at 1 year following enrollment was 24.2% for the TAVI group compared to 26.8% for the open AVR group ($p = 0.44$ for difference between groups). The upper limit of the 95% CI for the difference between groups was a 3.0% excess mortality in the TAVI group, which was well within the noninferiority boundary of 7.5%. Thus the criterion of noninferiority was met ($p = 0.001$). For the subgroup of patients who underwent TAVI by the transfemoral approach, results were similar with 22.2% mortality in the TAVI group compared with 26.4% mortality in the open AVR group ($p = 0.002$ for noninferiority). The secondary outcomes of cardiovascular mortality (14.3% vs 13.0%, $p = 0.63$) and rehospitalizations (18.2% vs 15.5%, $p = 0.38$) were not significantly different for the TAVI versus open AVR groups. The percent of patients in NYHA Class I or II at 1 year was similar between groups at 1 year, as was the improvement in the 6-minute walk test. On subgroup analysis, there was a significant effect for gender, with women deriving greater benefit than men ($p = 0.045$), and a significant effect for prior coronary artery bypass graft (CABG), with patients who had not had prior CABG deriving greater benefit in the TAVI group.

Certain complication rates showed significant differences between groups. Stroke or TIA at 1 year was higher for the TAVI group (8.3% vs 4.3%, respectively, $p = 0.04$). Vascular complications occurred in 18.0% percent of patients undergoing TAVI, compared with 4.8% in the open AVR group ($p = 0.01$), and major vascular complications were also higher in the TAVI group (11.3% vs 3.5%, $p = 0.01$). On the other hand, major bleeding was more common in the open group compared to TAVI (25.7% vs 14.7%, $p = 0.01$).

Reynolds et al published QOL results from the PARTNER trial in 2012. QOL outcomes were evaluated using the KCCQ summary score, the SF-12, and the EQ-5D. Of 699 patients in the trial, 628 completed baseline QOL measures. Patients in both the TAVI group and the surgical AVR group demonstrated significant improvements in all QOL measures over the 12 months following treatment. The TAVI group had superior improvement at 1 month on the KCCQ (mean difference, 9.9; 95% CI, 4.9 to 14.9; $p < 0.001$), but this difference was no longer present at 6 or 12 months. A similar pattern of results was reported for the SF-12 and EQ-5D measures.

Section Summary

The PARTNER RCT in high-risk patients who were eligible for surgical AVR reported no differences between TAVI and open AVR in terms of mortality at 1 year and most major secondary outcomes. The noninferiority boundaries for this trial included an upper limit of 7.5% absolute increase in mortality, but in actuality, the reported mortality for the TAVI group was lower than for the open group, although not significantly different. QOL was also similar at 1 year between the TAVI and AVR groups. Stroke or TIA was significantly more common for the TAVI group, occurring at a rate of almost 2 times that reported for open surgery. Other secondary outcomes were similar between groups, except for higher rates of vascular complications in the TAVI group and higher rates of major bleeding in the open surgery group. As in the first PARTNER cohort, there is concern for generalizability of results given that the patient selection process relied largely on the judgment of surgeons and cardiologists participating in the trial. In addition to this single RCT, several meta-analyses have compared outcomes between TAVI and open surgery using evidence that is primarily from nonrandomized comparative trials. These meta-analyses have concluded that there are no clear differences in mortality, or in secondary morbidity outcomes, between the two procedures.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

Does TAVI by alternative approaches (eg, transapical or transaxillary) achieve similar outcomes to those reported from the transfemoral approach?

The majority of all patients treated with TAVI, and all the patients enrolled in the PARTNER B trial, have been by the transfemoral approach. Other approaches, such as the transapical approach, have been used in patients with inadequate femoral access. There is a limited amount of evidence comparing outcomes from different approaches. In the PARTNER A trial, slightly less than one third of procedures were performed by the transapical approach, and there were no substantial differences in outcomes between the 2 approaches. The Edwards SAPIEN transcatheter heart-valve system has FDA approval for use by the transfemoral and transapical approach. There are no devices approved for use with other approaches such as the transiliac, transaxillary, or transaortic.

Systematic Reviews

A systematic review and meta-analysis of 20 nonrandomized studies comparing outcomes from the transfemoral and transapical approaches was published by Li et al in 2013. This review included 20 studies, 19 of which were prospective and one of which was retrospective. There was a total of 4267 patients treated by the transfemoral approach and 2242 patients treated by the transapical approach. Patients treated by the transfemoral approach had a lower 30-day mortality (7.5% vs 11.3%). There were no differences between groups in the incidence of stroke (3.8% vs 4.0%) or heart block requiring pacemaker (8.5% vs 7.5%).

Nonrandomized comparative studies. Some nonrandomized, comparative studies have compared outcomes for the transfemoral approach compared to the transapical approach. In a retrospective, multicenter from 4 centers in Europe enrolling 882 patients, outcomes were compared between the transfemoral (n = 793, 89.9% of total) and transapical (n = 89, 10.1% of total) approaches. Patients treated by the transapical approach were more severely ill, as demonstrated by a higher median EuroSCORE (27.0 vs 20.0, $p < 0.001$) and a higher median Society of Thoracic Surgeons Score (10.2 vs 6.7, $p < 0.001$). Patients treated by the transapical approach had a higher 30-day mortality (OR = 3.1, 95% CI, 1.4 to 6.8; $p = 0.004$) and a higher overall mortality at a median follow-up of 365 days (HR = 1.9; 95% CI, 1.2 to 2.9; $p = 0.004$). The transapical approach was associated with a lower risk for major bleeding complications (OR = 0.33; 95% CI, 0.12 to 0.90; $p = 0.03$).

Ewe et al included 107 consecutive patients undergoing TAVI, 47 by the transfemoral approach and 50 by the transapical approach. Mortality was not significantly different for the transfemoral approach versus the transapical approach at 30 days (11.1% vs 8.5%, respectively, $p = 0.74$) or at 1 year (19.8% vs 14.3%, respectively). Vascular complications were more common in the transfemoral group (18% vs 5%, respectively, $p = 0.05$). Fluoroscopy time and total radiation exposure was more reduced for the transapical approach.

A nonrandomized, comparative study reported higher complication rates with the transapical approach. Thomas et al used data from a European registry to compare patients undergoing TAVI by the transfemoral approach (n = 463) with patients undergoing TAVI by the transapical approach (n = 575). Complications were more frequent in the transapical group, but the transapical group also may have been more severely ill as judged by a higher EuroSCORE risk score. A publication from the UK TAVI registry evaluated risk

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406
Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014

factors for adverse outcomes in 877 TAVI procedures. On univariate analysis, TAVI by the transapical approach was associated with lower survival, although this relationship did not persist after controlling for demographic and clinical factors.

Section Summary

The only approaches for TAVI that have FDA approval are the transfemoral and transapical. There is some evidence comparing different approaches for TAVI. The highest quality evidence is for the transapical approach. This evidence includes a subgroup analysis from the PARTNER RCT, and nonrandomized comparative studies. In the RCT, there was not a mortality difference between the two approaches. In the nonrandomized studies, mortality is higher for patients treated by the transapical approach. However, patients treated by the transapical approach were more severely ill, with a higher predicted mortality at baseline. It is not possible to determine whether this difference in mortality is due to noncomparability of groups or due to the specific approach. In addition, since the transapical approach is generally used in patients who are not suitable for the transfemoral approach due to advanced vascular disease, the transapical approach is usually done out of necessity, not by choice of the surgeon. There is very little evidence on other approaches such as the transaxillary, transaortic and transiliac.

In 2013, the FDA expanded approved TAVI by the transapical approach to include both patients who are not candidates for open surgery and patients who are at high risk for open surgery.

What is the complication rate following TAVI?

A systematic review of complications associated with TAVI was published by Khatri et al in 2013. This study included all publications with at least 100 patients that had data on at least 1 type of complication. A total of 49 studies enrolling 16,063 patients were identified. The most common adverse event was heart block requiring a pacemaker insertion, which occurred in 13.1% of patients. Vascular complications occurred in 10.4% of patients. The third most common complication was acute renal failure requiring therapy in 4.9% of patients, and stroke was reported in 2.9% of patients. Other complications included moderate to severe aortic regurgitation in 4.5%, valve embolization in 1.3%, MI in 1.1% and coronary obstruction in 0.8%.

Some studies have specifically reported on 1 or more complications in large numbers of patients. Representative studies of this type will be reviewed here. The most common complications following TAVI are vascular complications related to the access site. Van Miegham et al pooled results from prospective databases on 986 patients undergoing transfemoral TAVI from 5 clinical centers in Europe. The rate of major vascular complications was 14.2%. Major bleeding occurred at a rate of 17.8% and life-threatening/disabling bleeding occurred at a rate of 11%.

Acute kidney injury is also relatively common following TAVI. In 218 patients treated at 1 academic medical center in the U.S., stage 2 or higher AKI occurred in 8.3% (18/218). Half of the patients with AKI (9/18) required dialysis. Mortality at 30 days (44.4% vs 3.0%, $p < 0.001$) and 1 year (55.6% vs 16.0%, $p < 0.001$) was much higher in patients with AKI compared to those without AKI. In a similar study of 248 patients from an academic center in Europe, stage 2 or higher AKI was more common, occurring in 35.9% of patients (89/248). Mortality was also increased at 30 days (13.5% vs 3.8%, $p < 0.001$) and at 1 year (31.5% vs 15.0%, $p < 0.001$) for patients with AKI.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

For patients with degenerated bioprosthetic valves or failed TAVI, does TAVI using the “valve-in-valve” approach improve outcomes?

The evidence on this question consists of case series, most of which are small. The largest case series published to date is from the Global Valve-in-Valve registry. This study included 202 patients from 38 cardiac centers with a prior surgical bioprosthetic valve replacement that had failed. The procedure was successful in 93.1% of attempts, and 95% of patients had 1 degree or less of aortic regurgitation postprocedure. Early adverse events occurred in 15.3%, with the most common events being malposition of the device and ostial coronary obstruction. Overall mortality was 8.3% at 30 days and 16.3% at 1 year. At 30 days' follow-up, 83.7% of patients were in NYHA functional Class I or II.

Other case series are smaller and generally from a single-center. A case series from Europe using the Medtronic CoreValve enrolled 27 patients from 1 cardiology center. There were 2 deaths within 30 days. Improvements in the aortic valve gradient and the degree of regurgitation were noted. Adverse events included stroke (7.4%), kidney failure (7.4%), life-threatening bleeding (7.4%), and access site complications (11.1%). Another case series from Europe treated 18 patients with a degenerated bioprosthetic valve and symptoms due to valve dysfunction. Implantation was successful in 17/18 patients. Complications included AKI in 3/18 patients, major bleeding in 4/18 patients, and major access site complications in 1/18 patients. At a median follow-up of 11 months, mortality was 5.6% and symptoms were improved with all patients in NYHA Class II or lower.

Smaller case series have reported on valve-in-valve implantation for patients with failed TAVI. For example, a publication from Canada reported on 21 patients with transcatheter valve failure due to aortic regurgitation. The procedure was successful in 19/21 patients; the remaining 2 patients required conversion to open surgery. Mortality at 30 days was 14.3% and at 1 year was 24%. Aortic regurgitation was absent in 4 patients, mild in 13 patients, and moderate in 2 patients.

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

Clinical input was received from 6 academic medical centers and 1 specialty society in 2011. At the time of vetting, FDA approval had not yet been granted for any TAVI device. Reviewers were mixed in support for a medically necessary indication for patients who are not surgical candidates. However, all reviewers indicated that they would consider this procedure medically necessary if FDA approval was granted. None of the reviewers expressed support for medical necessity in other patient populations, including patients who were at high risk for surgery, but were surgical candidates. Concerning patient selection criteria, most reviewers referred to the study selection criteria in the PARTNER trial and did not offer further options for objective patient selection.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

Summary

Transcatheter aortic valve implantation is a treatment for patients with severe aortic stenosis who require intervention, but who are a high or prohibitive risk for open surgery. There is currently 1 transcatheter aortic valve that is FDA-approved, the Edwards SAPIEN valve (Edwards LifeSciences, Irvine, CA).

For patients who are not surgical candidates due to excessive surgical risk, the PARTNER B trial reported results for patients treated with TAVI by the transfemoral approach compared to continued medical care with or without balloon valvuloplasty. There was a large decrease in mortality for the TAVI patients at 1 year compared to medical care. This trial also reported improvements on other relevant clinical outcomes for the TAVI group. There was an increased risk of stroke and vascular complications in the TAVI group. Despite these concerns, the overall balance of benefits and risks from this trial indicate that health outcomes are improved. For patients who are high risk for open surgery, but are operable candidates, the PARTNER A trial reported noninferiority for survival at 1 year compared to open surgery. In this trial, TAVI patients also had higher risks for stroke and vascular complications. Nonrandomized comparative studies of TAVI versus open surgery in high-risk patients have reported no major differences in mortality or in rates of stroke between the two procedures.

The PARTNER A trial also included a subgroup analysis comparing the transfemoral and transapical approaches and reported no outcome differences between the 2 approaches. Some nonrandomized comparative studies have reported higher mortality in patients treated by the transapical approach, but these comparisons are inconclusive because patients treated by the transapical route had a higher baseline risk for mortality. In 2013, the FDA expanded approved of TAVI by the transapical approach to include both patients who not candidates for open surgery and patients who are at high risk for open surgery. Based on the available evidence and the 2013 FDA approval, TAVI performed by either the transfemoral or transapical approach may be considered medically necessary in patients who are not suitable candidates for open surgery, and in patients who are operable candidates but at high risk for open surgery.

Transcatheter aortic valve implantation has also been used as a “valve-in-valve” treatment for degenerated bio-prosthetic valves and for failed transcatheter valves. The evidence on this indication consists only of case series and is insufficient to determine whether outcomes are improved compared to alternatives. As a result, TAVI used for a “valve-in-valve” approach is considered investigational.

Ongoing Clinical Trials

A search of online site ClinicalTrials.gov returned numerous ongoing trials of TAVI in various stages of evolution. The majority of these are single-arm trials evaluating the safety and efficacy of TAVI, using various types of valves, delivery systems, ancillary treatments, and outcomes. The following RCTs were identified that compared TAVI to alternative treatments, or compared outcomes of different types of valves:

- NCT01057173. Transcatheter compared to surgical valve implantation in patients with severe aortic stenosis. This is an RCT underway in Europe that is comparing TAVI with open surgical valve replacement using the Medtronic CoreValve. Estimated completion date is December 2018.
- NCT01314313. The PARTNER II Trial: Placement of Aortic Transcatheter Valves. This is an RCT underway in the U.S. that is comparing 2 types of the Edwards SAPIEN Valve system, the SAPIEN



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

valve with RetroFlex3 and the SAPIEN XT with NovaFlex. Estimated completion date is March 2018.

- NCT01240902. Safety and Efficacy Study of the Medtronic CoreValve^{®±} System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement. This is an RCT underway in the U.S. that is comparing TAVI with open surgical valve repair using the Medtronic CoreValve in patients who are at high risk for open surgery. Estimated completion date November 2017.
- NCT01586910. Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). This is an RCT of 2,500 patients at intermediate risk for surgery comparing TAVI with open AVR. The study is listed as recruiting, but no estimated completion date was provided.
- NCT01645202. A Comparison of Transcatheter Heart Valves in High Risk Patients with Severe Aortic Stenosis: The CHOICE trial. This is an RCT of 240 patients that compares TAVI using the Edwards SAPIEN valve to TAVI using the Medtronic CoreValve system. Estimated completion date for the primary outcomes is estimated to be March 2014.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Transcatheter Aortic Valve Implantation for Aortic Stenosis", 7.01.132, 12:2013.
2. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. *Circulation* 2005; 111(24):3316-26.
3. Coeytaux RR, Williams JW, Jr., Gray RN et al. Percutaneous heart valve replacement for aortic stenosis: state of the evidence. *Ann Intern Med* 2010; 153(5):314-24.
4. Lindroos M, Kupari M, Heikkila J et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. *J Am Coll Cardiol* 1993; 21(5):1220-5.
5. Bonow RO, Carabello BA, Kanu C et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation* 2006; 114(5):e84-231.
6. lung B, Cachier A, Baron G et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? *Eur Heart J* 2005; 26(24):2714-20.
7. Lieberman EB, Bashore TM, Hermiller JB et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. *J Am Coll Cardiol* 1995; 26(6):1522-8.
8. Food and Drug Administration. Summary of Safety and Effectiveness for the Edwards SAPIEN Transcatheter Heart Valve (PMA P11021). 2012. Available online at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM307195.pdf>.
9. FDA press release. FDA expands approved use of Sapien artificial heart valve. 2013. Available online at: <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm323478.htm>.
10. Figulla L, Neumann A, Figulla HR et al. Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy. A systematic review of current literature. *Clin Res Cardiol* 2011; 100(4):265-76.
11. Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010; 363(17):1597-607.
12. Reynolds MR, Magnuson EA, Lei Y et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. *Circulation* 2011; 124(18):1964-72.
13. Makkar RR, Fontana GP, Jiliahawi H et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med* 2012; 366(18):1696-704.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

14. Piazza N, Grube E, Gerckens U et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *EuroIntervention* 2008; 4(2):242-9.
15. Rodes-Cabau J, Webb JG, Cheung A et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol* 2010; 55(11):1080-90.
16. Zahn R, Gerckens U, Grube E et al. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. *Eur Heart J* 2011; 32(2):198-204.
17. Tamburino C, Capodanno D, Ramondo A et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. *Circulation* 2011; 123(3):299-308.
18. Gurvitch R, Wood DA, Tay EL et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. *Circulation* 2010; 122(13):1319-27.
19. Panchal HB, Ladia V, Desai S et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. *Am J Cardiol* 2013; 112(6):850-60.
20. Takagi H, Niwa M, Mizuno Y et al. A meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement. *Ann Thorac Surg* 2013; 96(2):513-9.
21. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011; 364(23):2187-98.
22. Reynolds MR, Magnuson EA, Wang K et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). *J Am Coll Cardiol* 2012; 60(6):548-58.
23. Li X, Kong M, Jiang D et al. Comparison 30-day clinical complications between transfemoral versus transapical aortic valve replacement for aortic stenosis: a meta-analysis review. *J Cardiothorac Surg* 2013; 8:168.
24. van der Boon RM, Marcheix B, Tchetché D et al. Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. *Ann Thorac Surg* 2013.
25. Ewe SH, Delgado V, Ng AC et al. Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach. *Ann Thorac Surg* 2011; 92(4):1244-51.
26. Thomas M, Schymik G, Walther T et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. *Circulation* 2011; 124(4):425-33.
27. Moat NE, Ludman P, de Belder MA et al. Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis: The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. *J Am Coll Cardiol* 2011; 58(20):2130-8.
28. Khatri PJ, Webb JG, Rodes-Cabau J et al. Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. *Ann Intern Med* 2013; 158(1):35-46.
29. Van Mieghem NM, Tchetché D, Chieffo A et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. *Am J Cardiol* 2012; 110(9):1361-7.
30. Genereux P, Kodali SK, Green P et al. Incidence and Effect of Acute Kidney Injury After Transcatheter Aortic Valve Replacement Using the New Valve Academic Research Consortium Criteria. *Am J Cardiol* 2012.
31. Dvir D, Webb J, Brecker S et al. Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves: Results from the Global Valve-in-Valve Registry. *Circulation* 2012.
32. Linke A, Woitek F, Merx MW et al. Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients with Failing Bioprosthetic Aortic Valves. *Circ Cardiovasc Interv* 2012; 5(5):689-97.
33. Latib A, Ielasi A, Montorfano M et al. Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. *EuroIntervention* 2012; 7(11):1275-84.
34. Toggweiler S, Wood DA, Rodes-Cabau J et al. Transcatheter valve-in-valve implantation for failed balloon-expandable transcatheter aortic valves. *JACC Cardiovasc Interv* 2012; 5(5):571-7.
35. Center for Medicare and Medicaid Services. Decision Memo for transcatheter aortic valve replacement (TAVR) (CAG-00430N). 2012. Available online at: <http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx>.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Blue Cross Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406
Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2013 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368, 33369
HCPCS	No codes
ICD-9 Diagnosis	395.0 thru 395.9, 396.0 thru 396.9, 424.1
ICD-9 Procedure	35.05, 35.22

Policy History

Original Effective Date: 03/19/2014
Current Effective Date: 03/19/2014
03/06/2014 Medical Policy Committee review
03/19/2014 Medical Policy Implementation Committee approval. New policy.
Next Scheduled Review Date: 03/2015

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 2. credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Transcatheter Aortic Valve Implantation for Aortic Stenosis

Policy # 00406

Original Effective Date: 03/19/2014

Current Effective Date: 03/19/2014

3. reference to federal regulations.

****Medically Necessary (or "Medical Necessity")** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. in accordance with nationally accepted standards of medical practice;
- B. clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.